文章摘要
潘 玲,李 萍,欧阳书堃,宋 惠,李佳欣.冠心舒通胶囊联合尼可地尔对冠心病稳定型心绞痛心血瘀阻型患者心功能、血液流变学和炎症因子的影响[J].,2022,(21):4125-4129
冠心舒通胶囊联合尼可地尔对冠心病稳定型心绞痛心血瘀阻型患者心功能、血液流变学和炎症因子的影响
Effects of Guanxinshutong Capsule Combined with Nicorandil on Cardiac Function, Hemorheology and Inflammatory Factors in Patients with Stable Angina Pectoris and Heart Blood Stasis Type
投稿时间:2022-05-26  修订日期:2022-06-22
DOI:10.13241/j.cnki.pmb.2022.21.022
中文关键词: 冠心舒通胶囊  尼可地尔  稳定型心绞痛  心血瘀阻型  心功能  血液流变学  炎症因子
英文关键词: Guanxinshutong capsule  Nicorandil  Stable angina pectoris  Heart blood stasis type  Cardiac function  Hemorheology  Inflammatory factor
基金项目:重庆市卫生和计划生育委员会中医药科技项目(ZY201703026)
作者单位E-mail
潘 玲 广州中医药大学研究生院 广东 广州 510006广州中医药大学附属重庆北碚中医院心内一科 重庆 400700 ppp0546@163.com 
李 萍 广州中医药大学附属重庆北碚中医院心内一科 重庆 400700  
欧阳书堃 广州中医药大学附属重庆北碚中医院心内一科 重庆 400700  
宋 惠 川北医学院附属遂宁市中医院心内科 四川 遂宁 629000  
李佳欣 成都中医药大学研究生院 四川 成都 610041  
摘要点击次数: 737
全文下载次数: 365
中文摘要:
      摘要 目的:观察冠心舒通胶囊联合尼可地尔在冠心病稳定型心绞痛心血瘀阻型患者中的应用价值。方法:根据随机数字表法,将广州中医药大学附属重庆北碚中医院2021年1月~2021年12月期间收治的冠心病稳定型心绞痛患者108例分为对照组(尼可地尔治疗,n=54)和观察组(冠心舒通胶囊联合尼可地尔治疗,n=54)。对比两组临床疗效、炎症因子水平、硝酸甘油片用量、西雅图心绞痛量表评分、中医证候总积分、血液流变学指标、心功能、不良反应。结果:治疗后,观察组的临床总有效率高于对照组(P<0.05)。治疗后,观察组西雅图心绞痛量表评分高于对照组,硝酸甘油片使用量少于对照组,中医证候总积分低于对照组(P<0.05)。治疗后,观察组左心室射血分数(LVEF)、心脏指数(CI)、左心室短轴缩短分数(LVFS)高于对照组(P<0.05)。治疗后,观察组全血黏度、血浆黏度及红细胞比容低于对照组(P<0.05)。治疗后,观察组白介素-1(IL-1)、肿瘤坏死因子-α(TNF-α)、髓过氧化物酶(MPO)、C反应蛋白(CRP)水平低于对照组(P<0.05)。两组不良反应发生率组间对比,无统计学差异(P>0.05)。结论:尼可地尔与冠心舒通胶囊联合治疗可提高冠心病稳定型心绞痛心血瘀阻型患者的治疗效果,改善其心功能和血液流变学,降低炎症因子水平,具有一定临床应用价值。
英文摘要:
      ABSTRACT Objective: To observe the application value of Guanxinshutong capsule combined with nicorandil in patients with stable angina pectoris and heart blood stasis type. Methods: According to the random number table method, 108 patients with stable angina pectoris and coronary heart disease who were treated in Chongqing Beibei Traditional Chinese Medicine Hospital Affiliated to Guangzhou University of Traditional Chinese Medicine from January 2021 to December 2021 were divided into control group (nicorandil treatment, n=54) and observation group (Guanxinshutong capsule combined with nicorandil treatment, n=54). The clinical efficacy, inflammatory factor levels, dosage of nitroglycerin tablets, Seattle angina pectoris scale score, traditional Chinese medicine syndrome total score, hemorheological indexes, cardiac function and adverse reactions were compared between the two groups. Results: After treatment, the total clinical effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, the score of Seattle angina pectoris scale of the observation group was higher than that of the control group, the dosage of nitroglycerin tablets was less than that of the control group, and the total score of traditional Chinese medicine syndrome was lower than that of the control group (P<0.05). After treatment, the left ventricular ejection fraction (LVEF), cardiac index (CI) and left ventricular short axis shortening fraction (LVFS) of the observation group were higher than those of the control group (P<0.05). After treatment, the whole blood viscosity, plasma viscosity and hematocrit of the observation group were lower than those of the control group (P<0.05). After treatment, the levels of interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α), myeloperoxidase (MPO) and C-reactive protein (CRP) of the observation group were lower than those of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The nicorandil and Guanxinshutong capsule treatment can improve the therapeutic effect of patients with stable angina pectoris and heart blood stasis, improve cardiac function and hemorheology, and reduce the level of inflammatory factors, it has certain clinical application value.
查看全文   查看/发表评论  下载PDF阅读器
关闭